


DIZ-3

Cat. No.:	HY-146812
CAS No.:	2675490-72-7
Molecular Formula:	C ₄₆ H ₄₄ F ₂ N ₈
Molecular Weight:	746.89
Target:	G-quadruplex
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	DIZ-3 is a selective multimeric G4 ligand based on a G4-ligand-dimerizing strategy. DIZ-3 intercalates into the G4-G4 interface, stabilizing the higher-order structure. DIZ-3 induces cell cycle arrest and apoptosis, and thus inhibits cell proliferation in alternative lengthening of telomere (ALT) cancer cells ^[1] .																		
In Vitro	<p>DIZ-3 (0-40 μM; 24 hours) inhibits the proliferation in an ALT cancer cell line^[1].</p> <p>DIZ-3 (0.6-2.5 μM; 24 hours) induces U2OS cell cycle arrest and Apoptosis in ALT cancer cells^[1].</p> <p>DIZ-3 (0.12, 0.25, 0.5 μM; 7 days) causes colony formation and wound healing assays carried out in U2OS cells^[1].</p> <p>DIZ-3 (0.12, 0.25, 0.5 μM; 24 h) significantly inhibits migration of U2OS cells^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Human bone osteosarcoma U2OS cells, normal BJ fibroblasts</td> </tr> <tr> <td>Concentration:</td> <td>0-40 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Caused a significant dose-dependent cytotoxic effect on U2OS cancer cells with an IC₅₀ of 2.1 μM. Induced much weaker growth inhibition on normal BJ fibroblasts with an IC₅₀ of 29.3 μM.</td> </tr> </table> <p>Apoptosis Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>U2OS cells</td> </tr> <tr> <td>Concentration:</td> <td>0.6, 1.2, 2.5 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>24 hours</td> </tr> <tr> <td>Result:</td> <td>Induced significant apoptosis in U2OS cells (the percentage of apoptotic cells increased from 10.1% to 24.9%).</td> </tr> </table> <p>Cell Cycle Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>U2OS cells</td> </tr> </table>	Cell Line:	Human bone osteosarcoma U2OS cells, normal BJ fibroblasts	Concentration:	0-40 μM	Incubation Time:	24 hours	Result:	Caused a significant dose-dependent cytotoxic effect on U2OS cancer cells with an IC ₅₀ of 2.1 μM. Induced much weaker growth inhibition on normal BJ fibroblasts with an IC ₅₀ of 29.3 μM.	Cell Line:	U2OS cells	Concentration:	0.6, 1.2, 2.5 μM	Incubation Time:	24 hours	Result:	Induced significant apoptosis in U2OS cells (the percentage of apoptotic cells increased from 10.1% to 24.9%).	Cell Line:	U2OS cells
Cell Line:	Human bone osteosarcoma U2OS cells, normal BJ fibroblasts																		
Concentration:	0-40 μM																		
Incubation Time:	24 hours																		
Result:	Caused a significant dose-dependent cytotoxic effect on U2OS cancer cells with an IC ₅₀ of 2.1 μM. Induced much weaker growth inhibition on normal BJ fibroblasts with an IC ₅₀ of 29.3 μM.																		
Cell Line:	U2OS cells																		
Concentration:	0.6, 1.2, 2.5 μM																		
Incubation Time:	24 hours																		
Result:	Induced significant apoptosis in U2OS cells (the percentage of apoptotic cells increased from 10.1% to 24.9%).																		
Cell Line:	U2OS cells																		

Concentration:	0.6, 1.2, 2.5 μ M
Incubation Time:	24 hours
Result:	Induced the apparent accumulation of cells in the S phase (increasing from 24.0% to 32.2%) in a dose-dependent manner.

REFERENCES

[1]. Ming-Hao Hu, et al. Dimeric aryl-substituted imidazoles may inhibit ALT cancer by targeting the multimeric G-quadruplex in telomere. Eur J Med Chem. 2020 Jan 15;186:111891.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA